Compare RGCO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | TNXP |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.4M | 194.9M |
| IPO Year | N/A | N/A |
| Metric | RGCO | TNXP |
|---|---|---|
| Price | $21.53 | $19.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $70.00 |
| AVG Volume (30 Days) | 12.0K | ★ 482.8K |
| Earning Date | 02-09-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $95,334,212.00 | $10,299,000.00 |
| Revenue This Year | $6.03 | $7.00 |
| Revenue Next Year | $2.73 | $718.07 |
| P/E Ratio | $17.04 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.50 | $6.76 |
| 52 Week High | $23.82 | $69.97 |
| Indicator | RGCO | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 63.32 |
| Support Level | $21.10 | $15.74 |
| Resistance Level | $22.34 | $17.07 |
| Average True Range (ATR) | 0.48 | 1.04 |
| MACD | 0.07 | 0.40 |
| Stochastic Oscillator | 42.86 | 81.44 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.